Embedded Files
Vaccine Adjuvant and Nanovaccine Innovation
Discovery of Novel Vaccine Adjuvants
Discovery of Novel Vaccine Adjuvants
Many vaccines fail to induce durable protection due to suboptimal immune stimulation. This project focuses on identifying novel immunomodulatory adjuvants including small-molecule TLR agonists, peptides, and natural compounds that enhance both humoral and cell-mediated immune responses. Emphasis is placed on affordability and scalability for veterinary and zoonotic vaccines.
Rational Antigen–Adjuvant Formulation
Rational Antigen–Adjuvant Formulation
Adjuvant efficacy depends on how antigens are formulated and delivered. This research evaluates antigen–adjuvant combinations using in vitro immune profiling and in vivo vaccination models to optimize immune magnitude, quality, and durability. Promising formulations are advanced toward translational testing.
Nanovaccine Platforms for Enhanced Immune Delivery
Nanovaccine Platforms for Enhanced Immune Delivery
We are developing next-generation nanovaccine platforms, including chitosan-based and mesoporous nanoparticles, to improve antigen stability, cellular uptake, and immune activation. These systems offer precise control over antigen release and immune engagement, enabling more effective and durable vaccination strategies.
Translational Evaluation in Large Animal Models
Translational Evaluation in Large Animal Models
To ensure real-world relevance, lead adjuvant formulations are evaluated in large animal models such as goats. This project bridges laboratory discovery and field application by assessing immune memory, durability, and safety in physiologically relevant systems, supporting the development of deployable veterinary vaccines.
Page updated
Google Sites
Report abuse